The number of burn wounds and chronic wounds is significant worldwide and expected to increase further due to the aging population. A substantial proportion of these wounds have necrotic tissue. These wounds require removal of the necrotic tissue, which is called debridement, to enable the wound to heal. There are multiple ways of debridement: surgical, mechanical (with the use of water), maggots and enzymatic (with the use of proteolytic enzymes).
Current debridements all have their disadvantages. Surgical and mechanical debridement require expensive staff and an operating theater, and is painful for the patient. Maggots are expensive and not patient friendly. And current enzymatic debriders options are expensive and are very painful for the patient.
SERDA – Stable Enzymatic Rapid Debriding Agent – offers an enzymatic wound debrider that shows fast speed of debridement, ease of use, high level of stability, and moderate irritation potential. SERDA is a hydrogel containing a proteolytic enzyme. The proteolytic enzyme digests the necrotic tissue/eschar which is composed of denatured matrix proteins (collagen, fibrin, etc.), removing the necrotic tissue and leaving the healthy tissue intact.
SERDA is ready for IND filing with the FDA to start human studies. Preclinical safety studies and chemistry, manufacturing and control activities have been completed.
Meet the team
Experienced MedTech executive with ample experience in fund-raising and creating and growing MedTech companies for complex Class III medical devices (including Sapiens Steering Brain Stimulation, acquired by Medtronic, and GTX medical). Over 25 years of experience in R&D project management, product management, creating and managing alliances, and early stage venturing, mainly for MedTech and Healthcare products.